{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 58 of 169', \"sponsor's medical expert should be contacted if there are any questions regarding concomitant\", 'or prior therapy.', 'Concomitant medication for conditions other than AD may be continued throughout the trial', 'without any change in dosage whenever possible.', 'The following concomitant medications related to AD treatment are permitted from screening', 'through safety follow-up (FU1 [Week 66] or FU2 [Week 82]):', 'Oral antibiotics, antiviral, or antifungal therapy for skin infections as', 'appropriate.', 'Stable doses of an emollient (see Section 9.4 for allowed emollients; subjects', 'must apply such emollients twice daily [or more, as needed] for at least', '14 days before baseline and throughout trial participation).', 'Oral anti-histamines.', 'In addition, the use of topical treatments is permitted during safety follow-up (from Week 52', \"or Week 68) at the investigator's discretion.\", '9.6 Prohibited medication and procedures', 'The following medications are prohibited during the trial from randomisation through', 'Week 52 (or Week 68):', 'TCS of any WHO class (except for subjects in open-label treatment).', 'Other topical medications used for the treatment of AD, such as TCI.', 'Use of ultraviolet A or B (UVA or UVB), psoralen + UVA (PUVA), other', 'phototherapy, or tanning beds.', 'Prescription emollients or emollients containing additives such as ceramide,', 'hyaluronic acid, urea, or filaggrin (unless treatment was initiated prior to', 'screening).', 'Three or more bleach baths per week.', 'Any prohibited topical treatments must be recorded as concomitant medication.', 'The following medications are prohibited during the trial from randomisation through safety', 'follow-up (FU1 [Week 66] or FU2 [Week 82]):', 'Investigational agents other than tralokinumab', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 59 of 169', 'Immunoglobulin or blood products', 'Systemic corticosteroids (nasal and inhaled corticosteroids are allowed)', 'Systemic treatment for AD with an immunosuppressive/ immunomodulating', 'agent (e.g., cyclosporine, mycophenolate mofetil, azathioprine, methotrexate,', 'Janus kinase inhibitors, interferon-gamma, or other biologics)', 'Allergen immunotherapy', 'Live (attenuated) vaccine', \"The sponsor's medical expert must be notified if a subject receives any of these medications\", 'during the trial.', '9.7 Rescue treatment', 'Initial treatment period and maintenance treatment period', 'If medically necessary (i.e., to control intolerable AD symptoms), rescue treatment for AD', 'may be provided to trial subjects at the discretion of the investigator. For the purpose of', 'efficacy analysis, subjects who receive rescue treatment during the initial treatment period', 'will be considered as non-responders, but they will continue IMP treatment if rescue consisted', 'of topical medications.', 'TCI may be used for rescue, but should be reserved for problem areas only, for example face,', 'neck, intertriginous and genital areas, etc. If possible, investigators should attempt to limit the', 'first step of rescue therapy to topical medications, and escalate to systemic medications only', 'for subjects who do not respond adequately after at least 14 days of topical treatment.', 'If a subject receives rescue treatment with systemic corticosteroids or non-steroidal systemic', 'immunosuppressive drugs (cyclosporine, methotrexate, mycophenolate mofetil, azathioprine,', 'etc.), IMP will be immediately discontinued (see Section 9.8.2, reasons for temporary', 'discontinuation of IMP). After the treatment with these medications is completed, IMP may', \"be resumed if deemed appropriate by the investigator and sponsor's medical expert, but not\", 'sooner than 5 half-lives after the last dose of systemic rescue medication.', 'Investigators should make every attempt to conduct efficacy and safety assessments (for', 'example disease severity scores, safety labs) immediately before administering any rescue', 'treatment. An unscheduled visit may be used for this purpose, if necessary.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}